fluoxetine has been researched along with ketamine in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.77) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (7.69) | 29.6817 |
| 2010's | 32 (61.54) | 24.3611 |
| 2020's | 13 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fang, VS; Meltzer, HY; Simonovic, M; Stanisic, D | 1 |
| Bouchal, RL; Martin, LL; Smith, DJ | 1 |
| Arora, RC; Meltzer, HY | 1 |
| Calixto, JB; Lin, J; Rodrigues, AL; Rosa, AO; Santos, AR | 1 |
| Fonteles, MM; Freitas, RM; Sousa, FC; Viana, GS | 1 |
| Cryan, JF; Dinan, TG; O' Connor, RM; Pusceddu, MM | 1 |
| Balster, RL; Burgdorf, J; Gross, AL; Kroes, RA; Leander, JD; Moskal, JR; Nicholson, KL; Stanton, PK; Zhang, XL | 1 |
| Al-Monajjed, R; Ciarimboli, G; Dobrivojevic, M; Edemir, B; Harrach, S; Holle, SK; Klassen, P; Massmann, V; Pavenstädt, H; Schlatter, E; Sindic, A | 1 |
| Cha, DS; Kim, RD; Mansur, RB; McIntyre, RS | 1 |
| Adeyemi, OI; Akanmu, MA; Owolabi, RA | 1 |
| Deng, CM; Gao, YY; Li, Y; Mu, YL; Ou, BC; So, JH; Tan, ZB; Tang, M; Wang, YQ; Zhang, LQ; Zhu, ZR | 1 |
| Satoh, N; Takahashi, K; Toyohira, Y; Yanagihara, N | 1 |
| Ford, N; Galletly, C; Ludbrook, G | 1 |
| Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP | 1 |
| Björkholm, C; Jardemark, K; Schilström, B; Svensson, TH | 1 |
| Hylton, A; Pittman, J | 1 |
| Ji, L; Li, H; Liu, W; Wang, Y | 1 |
| Eder, M; Hladky, F; Holsboer, F; Schmidt, MV; Stepan, J; Uribe, A | 1 |
| Colla, AR; Cunha, MP; Lieberknecht, V; Oliveira, Á; Pazini, FL; Rodrigues, AL; Rosa, JM | 1 |
| Chen, F; Sánchez, C; Waller, JA | 1 |
| du Jardin, KG; Elfving, B; Müller, HK; Sanchez, C; Wegener, G | 1 |
| du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G | 1 |
| García-Fuster, MJ; García-Sevilla, JA | 1 |
| Bove, M; Mhillaj, E; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P | 1 |
| Dong, C; Fujita, Y; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C | 1 |
| Berton, O; Browne, CA; Falcon, E; Lucki, I; Robinson, SA | 1 |
| Hales, CA; Houghton, CJ; Robinson, ESJ | 1 |
| Aguilar-Valles, A; Cao, R; Comai, S; De Gregorio, D; Eslamizade, MJ; Gobbi, G; Haji, N; Lacaille, JC; Luheshi, G; Matta-Camacho, E; Mechawar, N; Nadon, R; Nuñez, N; Popic, J; Rummel, C; Sharma, V; Sonenberg, N; Tanti, A; Turecki, G; Wiebe, S | 1 |
| Bettio, LB; Fraga, DB; Freitas, AE; Gonçalves, FM; Heinrich, IA; Leal, RB; Lopes, MW; Moretti, M; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB | 1 |
| Asth, L; Calo', G; Gavioli, EC; Guerrini, R; Holanda, VAD; Ruzza, C; Santos, WB | 1 |
| Chen, YJ; Chung, YJ; Lee, CW; Lee, YC; Li, CT; Lin, HC; Wu, HF | 1 |
| Cao, Y; Che, F; He, W; Sun, H; Wang, Y; Yao, Z; Zhang, H | 1 |
| Emmerzaal, TL; Geenen, B; Jacobs, L; Kozicz, T; Morava, E; Rodenburg, RJ; Verweij, V | 1 |
| Guarraci, FA; Marshall, GE; Meerts, SH | 1 |
| Antonio, CB; Barbosa, AR; Borsoi, M; Lima, MS; Medeiros, I; Neves, GA; Nunes, LED; Pranke, MA; Rates, SMK | 1 |
| Abelaira, HM; Borba, LA; Botelho, MEM; de Moura, AB; Fileti, ME; Garbossa, L; Goldim, MP; Gonçalves, CL; Ignácio, ZM; Petronilho, F; Quevedo, J; Réus, GZ; Rosa, T; Veron, DC | 1 |
| Li, YF; Li, ZH; Liu, WG; Ran, YH; Wang, YH; Yao, JQ; Yin, YY; Yuan, J; Zhang, LM | 1 |
| Brocardo, PS; Budni, J; Camargo, A; Fraga, DB; Mina, F; Olescowicz, G; Padilha, DA; Rodrigues, ALS | 1 |
| Bracke, F; Frieling, H; Leffler, A | 1 |
| Andreatini, R; Barreto, TF; Beijamini, V; Fracalossi, MPDS; Lopes, LM; Macedo, BL; Mori Ayub, JG; Tosta, CL | 1 |
| Golebiowska, J; Khoo, SY; Malikowska-Racia, N; Nikiforuk, A; Popik, P | 1 |
| Forsell, P; Lidell, V; Lindskog, M; Madjid, N; Nordvall, G; Ögren, SO; Sandin, J | 1 |
| Hillhouse, TM; Olson, R; Partridge, KJ | 1 |
| Aydın, Ş; Çivgin, ME; Dinçer Öner, S; Kılıç Tatlıcı, C; Kılıç, FS; Yazıcı, ZG; Yıldırım, C | 1 |
2 review(s) available for fluoxetine and ketamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review of FDA-approved treatment options in bipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Compounds; Benzodiazepines; Bipolar Disorder; Central Nervous System Stimulants; Depressive Disorder; Dibenzothiazepines; Drug Approval; Drug Combinations; Excitatory Amino Acid Antagonists; Fluoxetine; Humans; Isoindoles; Ketamine; Lamotrigine; Lurasidone Hydrochloride; Modafinil; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Thiazoles; Triazines; United States; United States Food and Drug Administration | 2013 |
50 other study(ies) available for fluoxetine and ketamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Ketamine as an anesthetic for obtaining plasma for rat prolactin assays.
Topics: 5-Hydroxytryptophan; Animals; Blood Specimen Collection; Catheterization; Drug Interactions; Fluoxetine; Ketamine; Male; Prolactin; Rats; Reserpine | 1978 |
Ketamine inhibits serotonin uptake in vivo.
Topics: Animals; Brain; Fenclonine; Fluoxetine; Ketamine; Male; Nialamide; Rats; Rats, Inbred Strains; Receptors, Serotonin; Reserpine; Serotonin; Spiperone | 1982 |
In vitro effect of phencyclidine and other psychomotor stimulants on serotonin uptake in human platelets.
Topics: Amphetamines; Blood Platelets; Fluoxetine; Humans; Ketamine; Phencyclidine; Serotonin; Serotonin Antagonists | 1980 |
Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.
Topics: Animals; Antidepressive Agents; Arginine; Ascorbic Acid; Behavior, Animal; Chlorides; Depression; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Fluoxetine; Free Radical Scavengers; Guanosine Monophosphate; Hindlimb Suspension; Imipramine; Immobilization; Ketamine; Male; Mice; Motor Activity; Nitric Oxide; Nitric Oxide Donors; Pain Measurement; Receptors, N-Methyl-D-Aspartate; S-Nitroso-N-Acetylpenicillamine; Swimming; Time Factors; Zinc Compounds | 2003 |
Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus.
Topics: Amines; Amitriptyline; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Humans; Ketamine; Male; Muscarinic Agonists; N-Methylaspartate; Pilocarpine; Pimozide; Rats; Seizures; Status Epilepticus | 2006 |
Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment.
Topics: Animals; Antidepressive Agents; Electroshock; Excitatory Amino Acid Antagonists; Fluoxetine; Hippocampus; Ketamine; Male; Maternal Deprivation; N-Methylaspartate; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Stress, Psychological | 2013 |
GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Topics: Acoustic Stimulation; Action Potentials; Animals; Antidepressive Agents; Brain; Conditioning, Operant; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Exploratory Behavior; Fluoxetine; Gene Expression Profiling; Ketamine; Long-Term Potentiation; Male; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Reflex, Startle; Swimming | 2013 |
The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Diazepam; Fluoxetine; HEK293 Cells; Histamine; Humans; Ion Transport; Ketamine; Kidney Tubules, Proximal; Male; Mice; Octamer Transcription Factor-3; Organic Cation Transport Proteins; Psychotropic Drugs; Quaternary Ammonium Compounds; Serotonin; Species Specificity | 2014 |
Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Fluoxetine; Ketamine; Mice; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate; Swimming; Synaptic Transmission | 2014 |
Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test.
Topics: Animals; Antidepressive Agents; Benzazepines; Benzothiazoles; Dizocilpine Maleate; Fluoxetine; Haloperidol; Ketamine; Male; Mice; Motor Activity; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate; Swimming | 2015 |
Effects of various pharmacological agents on the function of norepinephrine transporter.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Neurons; Animals; Cells, Cultured; Fluoxetine; Genistein; Humans; Ketamine; Nerve Endings; Nicotine; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Pentazocine; Sympathetic Nervous System; Synaptic Transmission | 2015 |
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Ketamine; Lithium Compounds; Lorazepam; Middle Aged; Quetiapine Fumarate | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depressive Disorder, Major; Disease Models, Animal; Drug Therapy, Combination; Fluoxetine; Glutamic Acid; Imipramine; Ketamine; Male; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Wistar; Stress, Psychological | 2015 |
Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluoxetine; Ketamine; Male; Olanzapine; Prefrontal Cortex; Pyramidal Cells; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Synaptic Transmission; Tissue Culture Techniques | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Ethanol; Excitatory Amino Acid Antagonists; Female; Fluoxetine; Hydrocortisone; Ketamine; Male; Zebrafish | 2015 |
The Role of Nitric Oxide in the Antidepressant Actions of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside in Insulin-Resistant Mice.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Antidepressive Agents; Combined Modality Therapy; Corticosterone; Depressive Disorder; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Activation; Fluoxetine; Imipramine; Insulin Resistance; Ketamine; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Physical Conditioning, Animal; Prefrontal Cortex; Ribonucleotides; Triazenes | 2016 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Chronic Disease; Diazepam; Disease Models, Animal; Dominance-Subordination; Fluoxetine; Haloperidol; Hippocampus; Ketamine; Lithium Compounds; Male; Mice, Inbred C57BL; Neural Pathways; Stress, Psychological; Tissue Culture Techniques; Voltage-Sensitive Dye Imaging | 2015 |
Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; Creatine; Depression; Disease Models, Animal; Female; Fluoxetine; Ketamine; Mice; Models, Biological; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2016 |
Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures.
Topics: Animals; Antidepressive Agents; Cells, Cultured; Dendritic Spines; Duloxetine Hydrochloride; Fluoxetine; Hippocampus; Ketamine; Piperazines; Rats, Sprague-Dawley; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Synapses; Vortioxetine | 2016 |
A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex.
Topics: Animals; Antidepressive Agents; Dose-Response Relationship, Drug; Fluoxetine; Frontal Lobe; Gene Expression Regulation; Glutamic Acid; Ketamine; Male; Neuronal Plasticity; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin; Sulfides; Time Factors; Vortioxetine | 2016 |
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Fluoxetine; Ketamine; Locomotion; Male; Memory Disorders; Piperazines; Rats; Recognition, Psychology; Selective Serotonin Reuptake Inhibitors; Sulfides; Swimming; Vortioxetine | 2016 |
Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Apoptosis; Autoreceptors; Blotting, Western; Brain; CASP8 and FADD-Like Apoptosis Regulating Protein; Cerebral Cortex; Clorgyline; Desipramine; Electroshock; Excitatory Amino Acid Antagonists; Fas-Associated Death Domain Protein; Fluoxetine; Idazoxan; Indans; Ketamine; Male; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Phosphoproteins; Phosphorylation; Rats; RNA-Binding Proteins; Thiazoles | 2016 |
Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Topics: Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; Immobility Response, Tonic; Ketamine; Male; Morpholines; Nerve Growth Factor; Norepinephrine; Rats; Reboxetine; Serotonin | 2017 |
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fluoxetine; Ketamine; Male; Mice; Mice, Inbred C57BL; Quinolones; Receptors, N-Methyl-D-Aspartate; Thiophenes | 2017 |
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.
Topics: Animals; Behavior, Animal; Brain; Buprenorphine; Disease Models, Animal; Excitatory Amino Acid Antagonists; Fluoxetine; Ketamine; Male; Mice; Mice, Inbred C57BL; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Social Behavior; Stress Disorders, Post-Traumatic; Stress, Psychological | 2018 |
Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats.
Topics: Acoustic Stimulation; Amphetamine; Analgesics; Animals; Antidepressive Agents; Association Learning; Central Nervous System Stimulants; Cocaine; Conditioning, Classical; Decision Making; Depressive Disorder, Major; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fluoxetine; Ketamine; Male; Models, Biological; Phencyclidine; Rats; Reaction Time; Time Factors | 2017 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depressive Disorder, Major; Eukaryotic Initiation Factor-4E; Female; Fluoxetine; Inflammation; Ketamine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-KappaB Inhibitor alpha; Phosphorylation; Protein Biosynthesis; Protein Serine-Threonine Kinases; Serotonin and Noradrenaline Reuptake Inhibitors; Synaptic Transmission; Tumor Necrosis Factor-alpha | 2018 |
Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine.
Topics: Agmatine; Animals; Antidepressive Agents; Brain; Corticosterone; Depression; Disks Large Homolog 4 Protein; Excitatory Amino Acid Antagonists; Female; Fluoxetine; Ketamine; Mice; Receptors, AMPA | 2018 |
NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain; Emotions; Fluoxetine; Helplessness, Learned; Imidazoles; Ketamine; Male; Mice; Nociceptin; Nortriptyline; Opioid Peptides; Receptors, Opioid; Spiro Compounds; Swimming | 2018 |
Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Topics: Amygdala; Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Electroshock; Fluoxetine; Ketamine; MAP Kinase Signaling System; Prefrontal Cortex; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2019 |
mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress.
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Imipramine; Ketamine; Rats | 2020 |
Chronic fluoxetine or ketamine treatment differentially affects brain energy homeostasis which is not exacerbated in mice with trait suboptimal mitochondrial function.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex I; Fluoxetine; Homeostasis; Ketamine; Mice; Mitochondria; Phenotype; Stress, Psychological | 2021 |
II. Antidepressants and sexual behavior: Acute fluoxetine, but not ketamine, disrupts paced mating behavior in sexually experienced female rats.
Topics: Animals; Antidepressive Agents; Copulation; Ejaculation; Female; Fluoxetine; Ketamine; Male; Motivation; Rats; Rats, Long-Evans; Sexual Behavior, Animal | 2020 |
Intermittent repeated stress but not ketamine changes mice response to antidepressants.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Fluoxetine; Imipramine; Ketamine; Male; Mice; Stress, Psychological | 2021 |
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.
Topics: Animals; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Fluoxetine; Ketamine; Male; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Wistar | 2021 |
The role of the excitation:inhibition functional balance in the mPFC in the onset of antidepressants.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Fluoxetine; Glutamic Acid; Inhibitory Postsynaptic Potentials; Interneurons; Ketamine; Male; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Inbred WF; Selective Serotonin Reuptake Inhibitors | 2021 |
Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice.
Topics: Animals; Corticosterone; Depression; Fluoxetine; Hippocampus; Ketamine; Mice; Receptors, Glucocorticoid | 2021 |
Antidepressants Are Poor Inhibitors of Heat-Evoked Ion Currents Mediated by TRPM2.
Topics: Adenosine Diphosphate Ribose; Amitriptyline; Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Fluoxetine; HEK293 Cells; Hot Temperature; Humans; Ketamine; Lidocaine; Mice; Paroxetine; Pregabalin; Sertraline; TRPM Cation Channels | 2022 |
S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine.
Topics: Animals; Antidepressive Agents; Calcium Carbonate; Excitatory Amino Acid Antagonists; Female; Fluoxetine; Gonadal Steroid Hormones; Ketamine; Male; Mice | 2022 |
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Ketamine; Male; Rats; Reinforcement Schedule; Reinforcement, Psychology | 2023 |
Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fluoxetine; Ketamine; Rats; Receptor, trkB | 2023 |
Methodological approach: using a within-subjects design in the marble burying assay.
Topics: Animals; Behavior, Animal; Buspirone; Calcium Carbonate; Disease Models, Animal; Female; Fluoxetine; Humans; Ketamine; Male; Mice | 2023 |
The investigation of antidepressant and anxiolytic effects of pregabalin and its mechanisms of action in rats.
Topics: Amitriptyline; Animals; Anti-Anxiety Agents; Antidepressive Agents; Epilepsy; Fluoxetine; Humans; Ketamine; Pregabalin; Rats; Rats, Wistar | 2023 |